SCHEMBL270276

SCHEMBL270276

Cc1ccccc1C[C@@H](N)[C@@H](O)Cc1ncccc1C(=O)NC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
ANO1 Q5XXA6 2/20 0.41
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
P2RX7 Q99572 1/20 0.36
NR3C2 P08235 1/20 0.36
HPGD P15428 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SGMS2 Q8NHU3 1/20 0.35
NPC1 O15118 1/20 0.35
AHR P35869 1/20 0.35
RAB9A P51151 1/20 0.35
ADORA2A P29274 1/20 0.35
KDR P35968 1/20 0.34
ALOX5AP P20292 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL268093 0.99 SMN1; SMN2 (0.42) SMN1; SMN2ANO1LMNATSHRP2RX7
SCHEMBL269117 0.91 SMN1; SMN2 (0.43) SMN1; SMN2ANO1LMNAP2RX7HPGD
SCHEMBL268964 0.90 KDM4E (0.41) SMN1; SMN2ANO1LMNAP2RX7HPGD
SCHEMBL268007 0.89 SGMS2 (0.40) SMN1; SMN2ANO1LMNAMAPTKDM4E
Hydrochloric Acid SCHEMBL268996 0.89 KDM4E (0.41) SMN1; SMN2ANO1LMNAP2RX7HPGD
SCHEMBL267669 0.89 ANO1 (0.45) SMN1; SMN2ANO1TSHRKMT2AALDH1A1
SCHEMBL270014 0.89 ANO1 (0.42) SMN1; SMN2ANO1LMNATSHRKMT2A
SCHEMBL268078 0.88 ANO1 (0.38) SMN1; SMN2ANO1LMNAP2RX7NR3C2
Hydrochloric Acid SCHEMBL269714 0.88 ANO1 (0.42) SMN1; SMN2ANO1LMNATSHRKMT2A
SCHEMBL269344 0.87 ANO1 (0.43) SMN1; SMN2ANO1LMNAHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133907-B2 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin ELI LILLY AND COMPANY (US) 2012-03-13 US disclosed
US-8133907-B2 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin ELI LILLY AND COMPANY (US) 2012-03-13 US disclosed
US-8133907-B2 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin ELI LILLY AND COMPANY (US) 2012-03-13 US disclosed
EP-1912946-B1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS LILLY CO ELI (US) 2009-05-27 EP disclosed
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors ELI LILLY AND COMPANY 2008-09-04 US disclosed
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors ELI LILLY AND COMPANY 2008-09-04 US disclosed
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors ELI LILLY AND COMPANY 2008-09-04 US disclosed
WO-2007015767-A1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors DPP4, DPP3, DPP7 SMN1; SMN2 4330/4885ANO1 3344/4885LMNA 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.